keyword
MENU ▼
Read by QxMD icon Read
search

granisetron

keyword
https://www.readbyqxmd.com/read/28393417/efficacy-and-safety-of-fosaprepitant-in-the-prevention-of-nausea-and-vomiting-following-highly-emetogenic-chemotherapy-in-chinese-people-a-randomized-double-blind-phase-iii-study
#1
L Q Yang, X C Sun, S K Qin, Y Cheng, J H Shi, Z D Chen, Q M Wang, H L Zhang, B Hu, B Liu, Q Y Zhang, Q Wu, D Wang, Y Q Shu, J Dong, B H Han, K M Wang, C X Dang, J L Li, H B Wang, B L Li, J G Lu, Z H Zhang, Y X Chen
The prevention of chemotherapy-induced nausea and vomiting was one of the most challenging supportive care issues in oncology, especially to highly emetogenic chemotherapy (HEC). A total of 645 patients were randomized into fosaprepitant group (fosaprepitant/placebo 150 mg d1 in combination with granisetron and dexamethasone) or aprepitant group (aprepitant/placebo 125 mg d1; 80 mg d2-d3 plus granisetron and dexamethasone).The primary endpoint was the percentage of patients who had a complete response (CR) over the entire treatment course (0-120 hr, overall phase [OP])...
April 10, 2017: European Journal of Cancer Care
https://www.readbyqxmd.com/read/28392676/differential-clinical-pharmacology-of-rolapitant-in-delayed-chemotherapy-induced-nausea-and-vomiting-cinv
#2
REVIEW
Noha Rashad, Omar Abdel-Rahman
Rolapitant is a highly selective neurokinin-1 receptor antagonist, orally administered for a single dose of 180 mg before chemotherapy with granisetron D1, dexamethasone 8 mg BID on day 2-4. It has a unique pharmacological characteristic of a long plasma half-life (between 163 and 183 hours); this long half-life makes a single use sufficient to cover the delayed emesis risk period. No major drug-drug interactions between rolapitant and dexamethasone or other cytochrome P450 inducers or inhibitors were observed...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28373467/efficacy-of-single-dose-first-generation-5-ht3-receptor-antagonist-and-dexamethasone-for-preventing-nausea-and-vomiting-induced-by-low-dose-carboplatin-based-chemotherapy
#3
Daizo Kaito, Hirotoshi Iihara, Norihiko Funaguchi, Junki Endo, Fumitaka Ito, Komei Yanase, Sayaka Toyoshi, Yuka Sasaki, Chiemi Hirose, Natsumi Arai, Mika Kitahora, Yasushi Ohno, Yoshinori Itoh, Shinya Minatoguchi
BACKGROUND: Carboplatin (CBDCA) is known to exhibit a high emetic risk among moderate-emetic risk anticancer drugs, and the dose of CBDCA varies in different therapies. In concurrent chemoradiotherapy (CCRT) for non-small cell lung cancer (NSCLC), the weekly administration of CBDCA (area under the curve (AUC) 2 mg/ml/min) and paclitaxel (PTX: 40 mg/m(2)) is frequently applied as standard therapy. However, the optimal antiemetic measures in the use of such low-dose CBDCA remain unclear...
April 2017: Anticancer Research
https://www.readbyqxmd.com/read/28352926/the-effect-of-requesting-a-reason-for-non-adherence-to-a-guideline-in-a-long-running-automated-reminder-system-for-ponv-prophylaxis
#4
Fabian O Kooij, Toni Klok, Benedikt Preckel, Markus W Hollmann, Jasper E Kal
BACKGROUND: Automated reminders are employed frequently to improve guideline adherence, but limitations of automated reminders are becoming more apparent. We studied the reasons for non-adherence in the setting of automated reminders to test the hypothesis that a separate request for a reason in itself may further improve guideline adherence. METHODS: In a previously implemented automated reminder system on prophylaxis for postoperative nausea and vomiting (PONV), we included additional automated reminders requesting a reason for non-adherence...
March 29, 2017: Applied Clinical Informatics
https://www.readbyqxmd.com/read/28231602/observational-case-series-evaluation-of-the-granisetron-transdermal-patch-system-sancuso-for-the-management-of-nausea-vomiting-of-pregnancy
#5
Tran N Le, Michael T Adler, Holly Ouillette, Pamela Berens, Judith A Smith
Objective The objective of this study was to observe the efficacy of antiemetic therapy (no emesis/retching episodes and no rescue medication use) when granisetron is administered via a transdermal patch system (TDS) in women who are 6 to 14 weeks pregnant when compared with oral ondansetron by evaluating the frequency of the use of rescue medications for control of nausea/vomiting of pregnancy (NVP). Methods This was an observational case series study to observe the potential benefits of granisetron TDS compared with oral ondansetron for management of NVP in pregnant patients during the first trimester...
February 23, 2017: American Journal of Perinatology
https://www.readbyqxmd.com/read/28211304/granisetron-and-carvedilol-can-protect-experimental-rats-againstadjuvant-induced-arthritis
#6
Yasmin Moustafa Ahmed, Basim Anwar Shehata Messiha, Ali Ahmed Abo-Saif
CONTEXT: Rheumatoid arthritis (RA), a disabling autoimmune disorder of the joints as well as other organs, affects about 1% of population. Unfortunately, all current treatments of RA cause severe gastrointestinal, renal and other complications. OBJECTIVE: We aimed to evaluate the possible antiarthritic effects of a serotonin 5-HT3 receptor blocker, granisetron, and a nonselective adrenergic receptor blocker, carvedilol, on complete Freund's adjuvant-induced RA in adult female albino rats...
April 2017: Immunopharmacology and Immunotoxicology
https://www.readbyqxmd.com/read/28205315/prevention-of-chemotherapy-induced-vomiting-in-children-receiving-multiple-day-cisplatin-chemotherapy-a-hospital-based-retrospective-cohort-study
#7
Kenji Kishimoto, Keiichiro Kawasaki, Atsuro Saito, Aiko Kozaki, Toshiaki Ishida, Daiichiro Hasegawa, Yoshiyuki Kosaka
BACKGROUND: Optimal prevention of chemotherapy-induced vomiting (CIV) has not been established for patients receiving cisplatin in divided doses. The aim of this study was to describe the incidence and risk factors of CIV in children who received multiple-day cisplatin chemotherapy. PROCEDURE: A total of 24 consecutive pediatric patients (age 0-19 years) who received multiple-day cisplatin chemotherapy in our hospital were enrolled. Patients with relapsed disease or primary intracranial tumor and those who received concurrent radiation therapy were excluded...
February 16, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28168082/simultaneous-determination-of-dexamethasone-ondansetron-granisetron-tropisetron-and-azasetron-in-infusion-samples-by-hplc-with-dad-detection
#8
Fu-Chao Chen, Lin-Hai Wang, Jun Guo, Xiao-Ya Shi, Bao-Xia Fang
A simple and rapid high-performance liquid chromatography with diode array detector (HPLC-DAD) method has been developed and validated for simultaneous quantification of five antiemetic agents in infusion samples: dexamethasone, ondansetron, granisetron, tropisetron, and azasetron. The chromatographic separation was achieved on a Phenomenex C18 column (4.6 mm × 150 mm, 5 μm) using acetonitrile-50 mM KH2PO4 buffer-triethylamine (25 : 74 : 1; v/v; pH 4.0). Flow rate was 1.0 mL/min with a column temperature of 30°C...
2017: Journal of Analytical Methods in Chemistry
https://www.readbyqxmd.com/read/28156636/rolapitant-for-the-prevention-of-nausea-in-patients-receiving-moderately-or-highly-emetogenic-chemotherapy
#9
Cindy K Nagy, Sujata Arora, Daniel Powers, Rebecca Anne Clark-Snow
224 Background: Nausea control remains an unmet need for patients receiving moderately or highly emetogenic chemotherapy (MEC, HEC). The objective of this analysis was to determine the effect of the neurokinin-1 (NK-1) receptor antagonist rolapitant (VARUBI) on the prevention of nausea in patients receiving either MEC or HEC. METHODS: Post hoc analyses of nausea from three randomized, double-blind, active-controlled, phase 3 clinical trials were performed for carboplatin-based MEC (n = 401), non-carboplatin-based MEC (n = 228), total MEC (n = 629), anthracycline/cyclophosphamide (AC)-based chemotherapy (n = 703), and cisplatin-based HEC (n = 1070)...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152708/influencing-antiemetic-prescribing-practices-and-funding-changes-through-evidence-based-guidelines
#10
Michael Wan, Aliya Pardhan, Erin Redwood, Andrea Crespo, Nita Lakhani, Leonard Kaizer
31 Background: In 2013 Cancer Care Ontario released updated antiemetic recommendations supporting the use of aprepitant-based combinations as 1(st) line therapy for highly emetogenic and 2(nd) line therapy for moderately emetogenic chemotherapy and discouraging the prolonged use of 5-HT3 antagonists. In 2014 changes were made in the Ontario drug formulary to align public funding to those recommendations. The impact of the changes in guidance and public funding on prescribing practices are now being analyzed...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28137449/the-binding-orientations-of-structurally-related-ligands-can-differ-a%C3%A2-cautionary-note
#11
Marc-David Ruepp, Hao Wei, Michele Leuenberger, Martin Lochner, Andrew J Thompson
Crystal structures can identify ligand-receptor interactions and assist the development of novel therapeutics, but experimental challenges sometimes necessitate the use of homologous proteins. Tropisetron is an orthosteric ligand at both 5-HT3 and α7 nACh receptors and its binding orientation has been determined in the structural homologue AChBP (pdbid: 2WNC). Co-crystallisation with a structurally-related ligand, granisetron, reveals an almost identical orientation (pdbid; 2YME). However, there is a >1000-fold difference in the affinity of tropisetron at 5-HT3 versus α7 nACh receptors, and α7 nACh receptors do not bind granisetron...
January 27, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28108820/prevention-of-chemotherapy-induced-nausea-the-role-of-neurokinin-1-nk1-receptor-antagonists
#12
Snežana M Bošnjak, Richard J Gralla, Lee Schwartzberg
Chemotherapy-induced nausea (CIN) has a significant negative impact on the quality of life of cancer patients. The use of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists (RAs) has reduced the risk of vomiting, but (except for palonosetron) their effect on nausea, especially delayed nausea, is limited. This article reviews the role of NK1RAs when combined with 5-HT3RA-dexamethasone in CIN prophylaxis. Aprepitant has not shown consistent superiority over a two-drug (ondansetron-dexamethasone) combination in nausea control after cisplatin- or anthracycline-cyclophosphamide (AC)-based highly emetogenic chemotherapy (HEC)...
May 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28061543/transdermal-granisetron-for-the-prevention-of-nausea-and-vomiting-following-moderately-or-highly-emetogenic-chemotherapy-in-chinese-patients-a-randomized-double-blind-phase-iii-study
#13
RANDOMIZED CONTROLLED TRIAL
Liu-Qing Yang, Xin-Chen Sun, Shu-Kui Qin, Ying-Xia Chen, He-Long Zhang, Ying Cheng, Zhen-Dong Chen, Jian-Hua Shi, Qiong Wu, Yu-Xian Bai, Bao-Hui Han, Wei Liu, Xue-Nong Ouyang, Ji-Wei Liu, Zhi-Hui Zhang, Yong-Qiang Li, Jian-Ming Xu, Shi-Ying Yu
BACKGROUND: The granisetron transdermal delivery system (GTDS) has been demonstrated effectiveness in the control of chemotherapy-induced nausea and vomiting (CINV) in previous studies. This is the first phase III study to evaluate the efficacy and tolerability of GTDS in patients receiving moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC) in China. METHODS: A total of 313 patients were randomized into the GTDS group (one transdermal granisetron patch, 7 days) or the oral granisetron group (granisetron oral 2 mg/day, ≥2 days)...
December 2016: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/28050395/variation-of-cost-among-anti-cancer-drugs-available-in-indian-market
#14
Bhanu Prakash Kolasani, Divyashanthi Chellathambi Malathi, Raghunatha Rao Ponnaluri
INTRODUCTION: Although cancer remains a major health problem all over the world, its treatment is limited by affordability of patients in a developing country like India. Information generated from cost analysis studies will be helpful for both the doctors in choosing the correct medicine for their patients and also for policy makers in successfully utilizing the meager resources that are available. AIM: The aim of the present observational study was to analyse the price variations of anti-cancer drugs available in India...
November 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28007031/comparative-safety-and-effectiveness-of-serotonin-receptor-antagonists-in-patients-undergoing-chemotherapy-a-systematic-review-and-network-meta-analysis
#15
Andrea C Tricco, Erik Blondal, Areti Angeliki Veroniki, Charlene Soobiah, Afshin Vafaei, John Ivory, Lisa Strifler, Roberta Cardoso, Emily Reynen, Vera Nincic, Huda Ashoor, Joanne Ho, Carmen Ng, Christy Johnson, Erin Lillie, Jesmin Antony, Derek J Roberts, Brenda R Hemmelgarn, Sharon E Straus
BACKGROUND: Although serotonin (5-HT3) receptor antagonists are effective in reducing nausea and vomiting, they may be associated with increased cardiac risk. Our objective was to examine the comparative safety and effectiveness of 5-HT3 receptor antagonists (e.g., dolasetron, granisetron, ondansetron, palonosetron, tropisetron) alone or combined with steroids for patients undergoing chemotherapy. METHODS: We searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials from inception until December 2015 for studies comparing 5-HT3 receptor antagonists with each other or placebo in chemotherapy patients...
December 23, 2016: BMC Medicine
https://www.readbyqxmd.com/read/28002447/influence-of-polymorphisms-in-the-htr3a-and-htr3b-genes-on-experimental-pain-and-the-effect-of-the-5-ht3-antagonist-granisetron
#16
Sofia Louca Jounger, Nikolaos Christidis, Britt Hedenberg-Magnusson, Thomas List, Peter Svensson, Martin Schalling, Malin Ernberg
The aim of this study was to investigate experimentally if 5-HT3 single nucleotide polymorphisms (SNP) contribute to pain perception and efficacy of the 5-HT3-antagonist granisetron and sex differences. Sixty healthy participants were genotyped regarding HTR3A (rs1062613) and HTR3B (rs1176744). First, pain was induced by bilateral hypertonic saline injections (HS, 5.5%, 0.2 mL) into the masseter muscles. Thirty min later the masseter muscle on one side was pretreated with 0.5 mL granisetron (1 mg/mL) and on the other side with 0...
2016: PloS One
https://www.readbyqxmd.com/read/27988172/-antiemetics-and-cardiac-effects-potentially-linked-to-prolongation-of-the-qt-interval-case-non-case-analysis-in-the-national-pharmacovigilance-database
#17
M Rochoy, M Auffret, J Béné, S Gautier
OBJECTIVES: Observational retrospective studies have linked domperidone and prolonged QT interval, ventricular arrhythmias and risk of sudden death. Since then, antiemetic prescription was applied to other molecules (including metopimazine). The aim of this study was to evaluate the profile of adverse cardiac effects associated with QT prolongation for each antiemetic available in France. METHODS: We conducted disproportionality analyses (case/non-case method), based on the observations recorded consecutively in the French national pharmacovigilance database between 2004 and 2013...
February 2017: Revue D'épidémiologie et de Santé Publique
https://www.readbyqxmd.com/read/27915445/granisetron-extended-release-injection-a-review-in-chemotherapy-induced-nausea-and-vomiting
#18
REVIEW
Emma D Deeks
An extended-release (ER) subcutaneously injectable formulation of the first-generation 5-HT3 receptor antagonist granisetron is now available in the USA (Sustol(®)), where it is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide combination chemotherapy regimens in adults. Granisetron ER is administered as a single subcutaneous injection and uses an erosion-controlled drug-delivery system to allow prolonged granisetron release...
December 2016: Drugs
https://www.readbyqxmd.com/read/27895421/carbon-monoxide-contributes-to-the-constipating-effects-of-granisetron-in-rat-colon
#19
Carmela Nacci, Margherita Fanelli, Maria Assunta Potenza, Valentina Leo, Monica Montagnani, Maria Antonietta De Salvia
AIM: To investigate the mechanisms underlying the potential contribution of the heme oxygenase/carbon monoxide (HO/CO) pathway in the constipating effects of granisetron. METHODS: For in vivo studies, gastrointestinal motility was evaluated in male rats acutely treated with granisetron [25, 50, 75 μg/kg/subcutaneous (sc)], zinc protoporphyrin IX [ZnPPIX, 50 μg/kg/intraperitoneal (ip)] and hemin (50 μmol/L/kg/ip), alone or in combination. For in vitro studies, the contractile neurogenic response to electrical field stimulation (EFS, 3, 5, 10 Hz, 14 V, 1 ms, pulse trains lasting 10 s), as well as the contractile myogenic response to acetylcholine (ACh, 0...
November 14, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27826967/palonosetron-induced-anaphylaxis-during-general-anesthesia-a-case-report
#20
Hyungjun Park, Kyunghwan Oh, Hoonhee Lee, Ji Hyang Lee, Sun Myoung Kang, So Young Park, Hyouk Soo Kwon, You Sook Cho, Hee Bom Moon, Tae Bum Kim
Palonosetron is a 5-hydroxytryptamine-3 (5-HT-3) receptor antagonist used for preventing postoperative nausea and vomiting. Compared with ondansetron and granisetron, it is a better drug because of prolonged action and minimal side effects. Some adverse effects of palonosetron have been reported. In this report, we describe a 37-year-old male who developed severe hypersensitivity reactions to palonosetron during surgery for kidney donation. His medical history was unremarkable, except for inguinal hernia with herniorrhaphy 8 years ago...
January 2017: Allergy, Asthma & Immunology Research
keyword
keyword
96075
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"